- Z-FA-FMK
-
- $61.00 / 1mg
-
2024-11-19
- CAS:197855-65-5
- Min. Order:
- Purity: 99.68%
- Supply Ability: 10g
|
| | Z-PHE-DL-ALA-FLUOROMETHYLKETONE Basic information |
| Product Name: | Z-PHE-DL-ALA-FLUOROMETHYLKETONE | | Synonyms: | Z-PHE-DL-ALA-FLUOROMETHYLKETONE;Carbamic acid,N-[(1S)-2-[(3-fluoro-1-methyl-2-oxopropyl)amino]-2-oxo-1-(phenylmethyl)ethyl]-,phenylmethyl ester;Nalpha-[(Benzyloxy)Carbonyl]-N-(4-Fluoro-3-Oxo-2-Butanyl)Phenylalaninamide z-fa-fmk;Nalpha-[(Benzyloxy)Carbonyl]-N-(4-Fluoro-3-Oxo-2-Butanyl)Phenylalaninamide;CS-1504;Z-Phe-DL-Ala-FMK;Benzyl ((2S)-1-((4-fluoro-3-oxobutan-2-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate;SARS coronavirus,SARS-CoV,RRMs,DNA fragmentation,DEVDase,Caspase,Cathepsin,Inhibitor,externalization of phosphatidylserine,Apoptosis,inhibit,Z FA FMK,reovirus replication,ZFAFMK | | CAS: | 197855-65-5 | | MF: | C21H23FN2O4 | | MW: | 386.42 | | EINECS: | | | Product Categories: | Inhibitors;API | | Mol File: | 197855-65-5.mol |  |
| | Z-PHE-DL-ALA-FLUOROMETHYLKETONE Chemical Properties |
| Boiling point | 630.5±55.0 °C(Predicted) | | density | 1?+-.0.06 g/cm3(Predicted) | | storage temp. | Inert atmosphere,2-8°C | | solubility | DMF: 5 mg/ml; DMSO: 5 mg/ml | | pka | 11.07±0.46(Predicted) | | form | White solid | | color | White to off-white |
| | Z-PHE-DL-ALA-FLUOROMETHYLKETONE Usage And Synthesis |
| Description | Z-FA-FMK is an irreversible inhibitor of cysteine proteases, including cathepsins B, L, and S, cruzain, and papain. It also inhibits effector caspases-2, -3, -6, and -7 (IC50 = 6-32 μM) without affecting the initiator caspases-8 and -10. Z-FA-FMK also modulates infection by certain bacteria, parasites, and viruses. It can be used both in cells and in vivo. | | Uses | Z-FA-FMK is an irreversible cysteine protease inhibitor. It also inhibits papain and cruzain. | | in vivo | Z-FA-FMK (1 mg/kg; intratumor injection; every 2 d, for 27 d; SCID mice with HT1080 xenograft) blocks reovirus infection in vivo[2].
Z-FA-FMK (8 mg/kg; i.v.; every 2 d, once; male BALB/c mice) markedly lessens the degree of impairment seen in D-GalN/TNF-α-induced kidney injury[3]. | Animal Model: | SCID mice with HT1080 xenograft (6-8 weeks)[2] | | Dosage: | 1 mg/kg | | Administration: | Intratumor injection; every 2 days, for 27 days | | Result: | Blocked reovirus replication activity in both tumor and heart tissues. |
| Animal Model: | Male BALB/c mice[3] | | Dosage: | 8 mg/kg | | Administration: | Intravenous injection; once, 1 hour later, intraperitoneal injection D-GalN (700 mg/kg) and TNF-α (15 μg/kg). | | Result: | Decreased in the D-GalN/TNF-α-induced degenerative changes.
Decreased in the number of activated caspase-3-positive tubular epithelial cell.
Increased in kidney GSH levels, CAT, SOD and GPx activities and decreased in kidney LPO levels, LDH activity, serum AST and ALT activities, uric acid, and urea levels were determined.
|
| | IC 50 | Cathepsin B; cathepsin L; Caspase-2; Caspase-3; Caspase-6; Caspase-7 |
| | Z-PHE-DL-ALA-FLUOROMETHYLKETONE Preparation Products And Raw materials |
|